ArticleQuantitative imaging in medicine and surgery2026
CEUS-based quantitative analysis of washout time in focal liver lesions affects hepatocellular carcinoma diagnosis.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: According to the American Association for the Study of Liver Diseases (AASLD) 2023 guidelines, contrast-enhanced ultrasound (CEUS) is a valuable complementary imaging modality for characterizing focal liver lesions (FLLs) that are not definitively diagnosed by contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMRI). This study compared the washout time of FLLs assessed by quantitative analysis (QA) and visual analysis (VA) on CEUS, evaluated their effects on CEUS Liver Imaging Reporting and Data System (LI-RADS) classification, and assessed their diagnostic performance in hepatocellular carcinoma (HCC). Furthermore, we sought to identify the QA-derived optimal washout time threshold for HCC diagnosis. Methods: Patients at high risk for HCC who underwent CEUS examinations at our hospital between April 2020 and October 2021 were retrospectively enrolled. All FLLs were pathologically confirmed. Washout time was assessed quantitatively using VueBox® software (QA) and visually by radiologists (VA). LR-5 was defined by CEUS LI-RADS (2017) as the category indicating liver lesions that are definitely HCC. QA LR-5 and VA LR-5 were defined as LR-5 categories assigned according to CEUS LI-RADS (version 2017) based on QA and VA, respectively. Furthermore, a modified washout time threshold was applied in the QA group to determine the optimal cutoff for HCC diagnosis, resulting in a new category termed "modified QA LR-5". The Wilcoxon signed-rank test was used to compare the washout time between QA and VA, and the diagnostic performance of VA LR-5, QA LR-5, and modified QA LR-5 for HCC was compared using the McNemar test. Results: A total of 233 FLLs from 225 patients were included, comprising 220 malignant lesions (184 HCCs) and 13 benign lesions. Median washout time of all FLLs was 55-59 seconds by QA and ≥60 seconds by VA (Z=-6.185, P<0.001). For HCCs, the median washout time was ≥60 seconds with both QA and VA, although QA detected earlier onset (Z=-6.022, P<0.001). For HCC diagnosis, QA LR-5 showed lower sensitivity (51.6% Conclusions: QA reveals earlier washout than VA, while both methods show good agreement with CEUS LI-RADS classification. Modifying the washout threshold from 60 to 40 seconds significantly improves the diagnostic performance of QA LR-5, supporting recalibration of CEUS LI-RADS for quantitative assessment, likely because QA is more sensitive in detecting early contrast clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.